Core Viewpoint - The announcement by Innovent Biologics regarding the successful completion of the GLORY-2 Phase III clinical trial for its GCG/GLP-1 dual receptor agonist, Ma Shidu, provides a new non-invasive weight loss option for the significant population of obese individuals in China, showing efficacy comparable to weight loss surgery [1][2][3] Group 1: Clinical Trial Results - The GLORY-2 trial achieved its primary endpoint and all key secondary endpoints, demonstrating significant weight loss in participants with a baseline BMI over 34 kg/m², with an average weight reduction of 20.08% compared to placebo [1][2] - The study included 462 participants, with a 2:1 random allocation to the Ma Shidu 9 mg group or placebo, and a treatment duration of 60 weeks [2] - Improvements were noted in various metabolic indicators, including waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels, with good tolerability and safety [1][2][3] Group 2: Market Implications - The high obesity prevalence in China, particularly among individuals with a BMI over 30 kg/m², highlights the need for effective non-invasive treatment options for this patient group, which currently relies heavily on metabolic surgery [1][2] - The successful results of the GLORY-2 trial position Ma Shidu as a promising new treatment option for managing obesity and related metabolic syndromes, potentially transforming the treatment landscape for this demographic [2][3] - Innovent Biologics plans to submit a marketing application for Ma Shidu 9 mg to the National Medical Products Administration (NMPA) to expedite access to this treatment for the Chinese population [3]